Ticagrelor for the treatment of acute coronary syndromes

TA236 Acute coronary syndromes - ticagrelor: review decision information

TA236 Acute coronary syndromes - ticagrelor: decision paper presented to the Institute's Guidance Executive (PDF 124 KB)

TA236 Acute coronary syndromes - ticagrelor: review proposal - March 2013 information

Appendix A: provisional matrix of stakeholders (PDF 102 KB)

Appendix B: proposal paper presented to the Institute's Guidance Executive (PDF 276 KB)

Acute coronary syndromes - ticagrelor: equality impact assessment (PDF 16 KB)

Acute coronary syndromes - ticagrelor: final appraisal determination  information

Acute coronary syndromes - ticagrelor: final appraisal determination document (PDF 185 KB)

Acute coronary syndromes - ticagrelor: response to consultee, commentator and public comments on the Appraisal Consultation Document (ACD) (PDF 124 KB)

Acute coronary syndromes - ticagrelor: consultee and commentator comments on the ACD

Acute coronary syndromes - ticagrelor: AstraZeneca (PDF 58 KB)

Acute coronary syndromes - ticagrelor: British Cardiovascular Society, British Cardiovascular Intervention Society and the Royal College of Physicians (PDF 313 KB)

Acute coronary syndromes - ticagrelor: British Heart Foundation (PDF 221 KB)

Acute coronary syndromes - ticagrelor: Royal College of Nursing (PDF 23 KB)

Acute coronary syndromes - ticagrelor: Department of Health (PDF 28 KB)

Acute coronary syndromes - ticagrelor: NHS Bradford and Airedale (PDF 570 KB)

Acute coronary syndromes - ticagrelor: NHS Oxfordshire (PDF 44 KB)

Acute coronary syndromes - ticagrelor: Daiichi Sankyo UK Ltd and Eli Lilly (PDF 45 KB)

Acute coronary syndromes - ticagrelor: comments on the ACD received from the public through the NICE website (PDF 30 KB)

Acute coronary syndromes - ticagrelor: appraisal consultation

Acute coronary syndromes - ticagrelor: appraisal consultation document information

Acute coronary syndromes - ticagrelor: evaluation report

Acute coronary syndromes - ticagrelor: pre-meeting briefing (PDF 173 KB)

Acute coronary syndromes - ticagrelor: Evidence Review Group report (PDF 859 KB)

Acute coronary syndromes - ticagrelor: Evidence Review Group report - factual accuracy check (PDF 81 KB)

Acute coronary syndromes - ticagrelor: manufacturer submission

Acute coronary syndromes - ticagrelor: AstraZeneca (PDF 2.72 MB)

Acute coronary syndromes - ticagrelor: impact of revised resource use on results submitted to NICE (PDF 76 KB)

Acute coronary syndromes - ticagrelor: clarification

Acute coronary syndromes - ticagrelor: NICE clarification letter (PDF 28 KB)

Acute coronary syndromes - ticagrelor: manufacturer response to the NICE clarification letter (PDF 655 KB)

Acute coronary syndromes - ticagrelor: patient group, professional group and NHS organisation submission statements

Acute coronary syndromes - ticagrelor: British Cardiovascular Intervention Society and British Cardiovascular Society (PDF 101 KB)

Acute coronary syndromes - ticagrelor: Oxfordshire PCT (PDF 22 KB)

Acute coronary syndromes - ticagrelor: expert written personal statements

Acute coronary syndromes - ticagrelor: Clark (PDF 77 KB)

Acute coronary syndromes - ticagrelor: Curzon (PDF 204 KB)

Acute coronary syndromes - ticagrelor: Fell (PDF 58 KB)

Acute coronary syndromes - ticagrelor: Gerschlick (PDF 29 KB)

Acute coronary syndromes - ticagrelor: Miller (PDF 98 KB)

Acute coronary syndromes - ticagrelor: final matrix of consultees and commentators (PDF 50 KB)

Acute coronary syndromes - ticagrelor: final scope (PDF 45 KB)

Acute coronary syndromes - ticagrelor: response to consultee and commentator comments on the provisional matrix (PDF 51 KB)

Acute coronary syndromes - ticagrelor: response to consultee and commentator comments on the draft scope (PDF 174 KB)